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Abstract
The discovery of short regulatory RNAs has recently directed the attention of
scientists to parts of the genome that previously had been regarded as “junk” DNA
because they did not encode protein products. The revelation that even protein-
noncoding sequences had biological functions began the era of discovering the
world of noncoding RNAs (ncRNAs). Of these ncRNAs, microRNAs (miRNAs) and
long noncoding RNAs (lncRNAs) are the most numerous and best-known ncRNA
groups. miRNAs and lncRNAs are important regulators of hematopoiesis, and their
abnormal function has serious implications for phenotypes. Deregulation of these
ncRNAs is found in hematopoietic disorders, and they also contribute to the devel-
opment and progression of myelodysplastic syndromes (MDS). Properties of
ncRNAs such as stability and tissue specificity make these molecules highly prom-
ising diagnostic and prognostic markers as well as interesting therapeutic targets.
This chapter summarizes our knowledge on the contribution of ncRNAs to the
pathogenesis of MDS and discusses their potential applicability in disease diagnos-
tics and prognosis.
Keywords: myelodysplastic syndromes, noncoding RNAs, microRNAs, long
noncoding RNAs, pathogenesis
1. Introduction
Myelodysplastic syndromes (MDS) are a heterogeneous group of clonal hema-
topoietic stem cell (HSC) disorders, characterized by dysplastic and ineffective
blood cell production, with a tendency for transformation to acute myeloid leuke-
mia (AML). The diagnosis is generally suspected based on the presence of an
abnormal complete blood count and is confirmed by performing bone marrow
(BM) aspiration and biopsy, demonstrating morphological evidence of dysplasia.
A number of additional tests, including cytogenetics, flow cytometry, and molecu-
lar genetics, are needed to complete the laboratory evaluation of patients with
MDS [1].
Because of the large heterogeneity of MDS, the development of additional
molecular tools able to refine the prognostic scoring system, to predict outcome,
and to monitor the response to treatment is required. Recently, application of new
high-throughput methods such as next-generation sequencing (NGS) has identified
recurrent somatic mutations in MDS cells. In particular, point mutations in the
TP53, EZH2, ETV6, RUNX1, and ASXL1 genes have been shown to be associated
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with specific clinical features and poor overall survival, independent of established
risk factors [2]. Even though approximately 78% of MDS patients carry at least one
oncogenic mutation [3], there is a long list of mutations in more than 50 genes with
often unclear etiology, complicating the use of somatic mutations as simple and
universal markers of MDS prognosis.
Concerning MDS pathogenesis, substantial progress has been made in recent
years. A vast literature has become available regarding the spectrum of cytogenetic
abnormalities, gene mutations, epigenetic modifications, gene expression patterns,
and deregulated signaling pathways (e.g., apoptosis, proliferation, immune
response, chromatin remodeling, RNA-splicing machinery, oxidative damage/DNA
repair, microenvironment interactions, and others) associated with the disease. In
this review, we discuss the contributions of noncoding RNAs (ncRNAs) to the
pathogenesis of MDS as well as their potential applications as novel molecular
markers for clinical purposes.
2. Noncoding RNAs
At the end of the last millennium, the importance of noncoding RNAs was
completely unknown. Up to that point, the scientific community focused on genes
that coded for proteins. The classic dogma of molecular biology postulated that
DNA was transcribed into RNA, which was then translated into protein, ignoring
all non-protein-coding sequences. Only in 1993 did the importance of miRNAs
begin to be revealed. The discovery of the first miRNA, lin-4, from Caenorhabditis
elegans [4, 5] initiated a new scientific era that definitively overcame the absolute
sanctity of the central dogma. Interest in this field was further stimulated by the
finding that almost all of the mammalian genome was transcribed at some level
[6], raising speculation that much of this pervasive transcription was likely func-
tional. This idea was epitomized by the ENCODE (Encyclopedia of DNA
Elements, www.encodeproject.org) consortium that claimed to have assigned
“biochemical functions for 80% of the genome” [7, 8]. From the beginning of this
era, researchers identified thousands of previously unknown types of noncoding
RNAs and indeed started to reveal their multiple functions affecting various fea-
tures of cells.
2.1 Types of noncoding RNAs
Functional ncRNAs can be divided into two main types: infrastructural and
regulatory ncRNAs. Infrastructural ncRNAs appear to have housekeeping roles in
translation and splicing; they include species such as ribosomal RNAs (rRNAs),
transfer RNAs (tRNAs), and small nuclear RNAs (snRNAs) that are involved in
splicing events. Regulatory ncRNAs, including long noncoding RNAs (lncRNAs),
microRNAs (miRNAs), and piwi-interacting RNAs (piRNAs) are involved in the
modification and interactions with other RNAs. However, ncRNAs can also be
categorized on the basis of length (small, 18–31 nt; medium, 31–200 nt; and long,
>200 nt), structure (circular RNAs (circRNAs)), or subcellular localization (small
nuclear RNAs (snRNAs) and small nucleolar RNAs (snoRNAs)). Other infrequent
ncRNA types such as trans-spliced transcripts and macroRNAs that comprise enor-
mous genomic distances, or multigene transcripts containing several genes or even
the whole chromosome, further complicate efforts at systematic classification [9].
Moreover, clear categorization of ncRNA species is difficult, as many ncRNA tran-
scripts often share properties of several categories. The major classes of ncRNAs are
summarized in Table 1.
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Of the various classes of ncRNAs, miRNAs and lncRNAs are the most numerous
and are probably the best-known ncRNA groups (numbers of publications
concerning miRNAs and lncRNAs are shown in Figure 1). Having different regula-
tory functions, these types of ncRNAs are important players in the majority of
cellular processes, including hematopoiesis, and their abnormal function has serious
implications for phenotypes. Deregulation of miRNAs and lncRNAs is frequently
found in hematopoietic disorders, contributing substantially to the disease devel-
opment and progression. Therefore, the following sections of this review will pri-
marily focus on these two categories of ncRNAs and their functions in MDS.
3. MicroRNAs
miRNAs are short single-stranded noncoding RNA molecules of approximately
21–25 nt in length. Their sequences are highly conserved in both plants and animals
and are thought to be an evolutionarily ancient component of gene regulation.
miRNAs posttranscriptionally regulate gene expression through the RNA
ncRNA class Description Description Length
rRNA Ribosomal
RNA
RNA that is directly incorporated into the
ribosome
Large subunit (5S–121 nt,
5.8S–156 nt, 28S–5070 nt)
Small subunit (18S–1869 nt)
tRNA Transfer
RNA
Transfer amino acids to the ribosome for protein
construction
76–90 nt
snRNA Small
nuclear
RNA
Small RNA located in the nucleus, involved
in spliceosomes (e.g., U1, U2, U5, U4, and
U6), RNA modification, and other
functions. Also commonly referred to as U-RNAs
150 nt
snoRNA Small
nucleolar
RNA
RNA located in the nucleolus, mostly involved in
modification of other RNAs, such as rRNA (C/D-
box and H/ACA box snoRNAs) or spliceosomal
RNA (scaRNA)
60–250 nt
miRNA microRNA A short single-stranded RNA that usually
suppresses the translation of target mRNA by
binding to 3′ UTR through RNA interference
pathways
21–25 nt
siRNA Small
interfering
RNA
Double-stranded RNA that guides sequence-
specific degradation of target mRNA through
RNA interference pathway
10–25 bp
piRNA Piwi-
interacting
RNA
A large class of small ncRNAs involved in
retrotransposon silencing through interactions
with piwi proteins
26–31 nt
Y-RNA Y RNA Components of the Ro ribonucleoprotein
complex, repressing its activity. It is also required
for DNA replication
69–112 nt
circRNA Circular
RNA
RNA derived from precursor mRNAs forming
covalently closed continuous loop. It is more
resistant to exonuclease-mediated degradation
1–5 exons
lncRNA Long
noncoding
RNA
A non–protein-coding transcript with >200 nt >200 nt
Table 1.
The major categories of ncRNAs.
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interference pathway. During the last decade, it has repeatedly been proven that
miRNAs play crucial roles in a wide variety of biological processes such as develop-
ment, differentiation, proliferation, and apoptosis. Because miRNAs influence the
expression of genes involved in fundamental signaling pathways, their deregulation
often triggers various pathological processes, including cardiovascular diseases,
neurological diseases, and cancer.
The first miRNA, lin-4 from Caenorhabditis elegans, was discovered in the early
1990s [4, 5]. However, miRNAs were not recognized as a distinct class of biological
regulators until the early 2000s. To date, thousands of miRNAs have been identified
in humans and other species, and miRNA online sequence repositories, such as the
miRBase database (www.mirbase.org), are available. According to the current ver-
sion of the miRBase database (release 22), there are 1982 precursor miRNAs and
2693 mature miRNAs known in humans.
The biogenesis of miRNAs is a multistep process. miRNA genes are transcribed
from genomic DNA by RNA polymerase II, resulting in primary miRNA (pri-
miRNA) transcripts that usually encode sequences for several miRNAs. In the
nucleus, these pri-miRNAs are cleaved by endonuclease Drosha, releasing approxi-
mately 70 nucleotide-long hairpin precursor miRNAs (pre-miRNAs). Pre-miRNAs
are transported into the cytoplasm, where they are cleaved by Dicer into dsRNA
duplexes containing both mature miRNA strand (miRNA) and its complementary
strand (miRNA*). In general, the mature miRNA strands are preferentially loaded
into the miRNA-induced silencing complex (miRISC), whereas the complementary
strands are excluded and degraded. Once processed from the hairpin and loaded
Figure 1.
Numbers of publications found on Pubmed using search terms: (a) miRNA (b) lncRNA, (c) MDS and
miRNA, and (d) MDS and lncRNA (since the year 2000).
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into the silencing complex, the miRNA pairs with messenger RNA (mRNA) to
direct posttranscriptional repression. At sites with extensive pairing complemen-
tarity, the miRNA directs argonaute-catalyzed mRNA cleavage. More commonly,
however, the miRNAs direct translational repression, mRNA destabilization, or a
combination of the two [10].
It has been shown that an individual miRNA is able to control the expression of
more than one target mRNA and that each mRNA may be regulated by several
miRNAs. Generally, it is believed that miRNAs regulate more than 30% of protein-
coding genes in the human genome [11]. The ability of miRNAs to interact with
thousands of mRNAs has raised intensive interest in their role in physiological and
pathological conditions. Like mRNAs, the majority of miRNAs are expressed in
tissue-specific manners. For example, miR-122 is preferentially expressed in liver
[12], miR-124 in neurological tissues [13], miR-133 in muscles [14], and miR-208a
in heart [15]. Moreover, it has been demonstrated that changes in the spectrum of
tissue miRNAs correlate with various pathophysiological conditions [16].
3.1 Extracellular miRNAs
In recent years, cell-free circulating miRNAs have been found in various body
fluids such as blood, cerebrospinal fluid, saliva, and urine [17]. The first extracellu-
lar small RNAs were observed in blood in 2004 [18]. Unlike the comprehensively
described function of cellular miRNAs, the function of miRNAs present in the
extracellular environment remains somewhat speculative. However, a growing
body of evidence has suggested that these molecules are not mere leftovers of
cellular degradation without any specific functions, but that active exchange of
miRNAs between cells can play an important role in long-distance cell-to-cell com-
munication.
In 2008, Mitchell et al. [19] reported that extracellular miRNAs were stable in
human plasma/serum. This high stability of circulating miRNAs despite high levels
of RNase activity in blood indicates that circulating miRNAs must somehow be
protected from degradation. To date, a number of miRNA carriers have been
described: membrane-derived vesicles (shedding vesicles, exosomes), lipoproteins,
and ribonucleoprotein complexes (with argonaute-2 (AGO2) or nucleophosmin 1
(NPM1) proteins) have been found to transport extracellular miRNAs. It has been
reported that the sorting of miRNAs into various types of vesicles can be selective.
Diehl et al. [20] compared the content of miRNAs in microvesicles and their
maternal cells. These authors demonstrated a significantly varied spectrum of
miRNAs in both samples, suggesting a selective packaging of miRNAs into
microvesicles.
3.2 miRNAs in normal hematopoiesis
The differentiation and homeostasis of the hematopoietic system requires com-
plex and interconnected molecular networks that need careful regulation. During
the last decade, the role of miRNAs in the hematopoietic system has been exten-
sively studied, and many miRNAs serving as critical regulators of both normal
immune functions and diseases have been discovered (Figure 2).
The first study of a role of miRNAs in the differentiation of the immune system
showed that forced expression of miR-181 in hematopoietic stem cells (HSCs) mark-
edly increased the number of B lymphocytes, with a concomitant reduction of T
lymphocytes [21]. Since then, other miRNAs specific for the maintenance of the
“stemness” of HSCs and for the development of individual blood cell lines have been
determined. For example, miR-125a was found to be sufficient as a single miRNA to
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modulate HSC self-renewal and numbers and to protect lineage-negative progenitor
cells from apoptosis [22]. A key miRNA that regulates granulocytic differentiation
and function is miR-223. This miRNA shows a highly lineage-specific pattern of
expression with low levels in HSCs and common myeloid progenitors. The expres-
sion of this miRNA is steadily upregulated during differentiation to granulocytes and
is repressed during differentiation to the alternative monocytic fate [23]. miR-451 is
expressed predominantly in erythroid cells, and its expression is significantly
increased during maturation of erythrocytes. In contrast, miR-221 and miR-222 are
downregulated during erythroid differentiation. This downregulation enables the
expression of their target gene KIT (KIT proto-oncogene receptor tyrosine kinase,
CD117), whose activation triggers erythroblast expansion [24]. Another miRNA,
miR-150, is highly expressed inmature lymphocytes, whereas it is not active in HSCs.
The target gene of miR-150 is transcription factor MYB (myeloblastosis) that regu-
lates lymphocyte development [25]. miR-155, with its high levels in activated B cells,
T cells, and monocytes, also participates in lymphoid differentiation. The develop-
ment of B cells is positively regulated by miRNAs encoded by cluster miR-17-92. This
cluster of miRNAs inhibits the expression of the apoptotic gene BIM (proapoptotic
BH3-only Bcl-2 family member) and thus plays a key role in pro-B cells to pre-B cells
transition [26]. In our laboratory, we analyzed miRNA expression in individual cell
types from the peripheral blood of healthy individuals and determined a panel of 13
miRNAs whose expression profile enables differentiation of individual blood cell
lines and determination of the cellular origin of in vitro cultured lines [27].
3.3 miRNAs in malignant hematopoiesis
In oncogenesis, miRNAs act both as oncogenes and as tumor suppressors.
Mechanisms of deregulation are similar to those of protein-coding genes (chromo-
some aberrations, mutations, and epigenetic modifications). In 2002, the loss of two
miRNAs (miR-15a and miR-16-1) due to a deletion in the 13q14 region in patients
with chronic lymphocytic leukemia was described for the first time as directly
associated with malignant disease [28]. In subsequent years, several miRNAs with
key roles in the pathogenesis and prognosis of hematological malignancies were
detected.
Figure 2.
Schema of lineage differentiation in hematopoiesis and miRNAs involved in the process. CLP—common
lymphoid progenitor, CMP—common myeloid progenitor, ETP—early thymic progenitor, GMP—granulocyte
macrophage progenitor, HSC—hematopoietic stem cell, MEP—megakaryocyte erythroid progenitor,
NK—natural killer cell, RBC—red blood cell.
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Several publications involved investigations of the role of miRNAs in AML.
miRNA expression profiling revealed marked differences in miRNA expression
between common cytogenetic subtypes of AML. Jongen-Lavrencic et al. [29] iden-
tified upregulation of several miRNAs (miR-382, miR-134, miR-376a, miR-127,
miR-299-5p, and miR-323) in AML patients with t(15;17) and significant
downregulation of miRNAs from let-7 family in AML with t(8;21) as well as in AML
with inv(16). Moreover, miRNA signatures have been reported to be associated
with recurrent molecular abnormalities in cytogenetically normal AML [30]. For
example, upregulation of miR-10, let-7, and miR-29 family members and
downregulation of miR-204 and miR-128a were found in AML with NPM1muta-
tions [31] and high expression of miR-181a and miR-181b was associated with
CEBPA (CCAAT/enhancer binding protein alpha) mutations [32].
3.4 miRNA deregulation in MDS
Several preliminary reports focused on identification of miRNA expression pro-
files that were either common in MDS or specific for individual MDS subcategories.
For example, Pons et al. [33] measured levels of expression of 25 mature miRNAs in
mononuclear cells (MNCs) of MDS patients. The authors reported overexpression
of miRNA cluster miR-17-92 in MDS and differential expression of miR-15a and
miR-16 between low- and high-risk subgroups of patients. Hussein et al. [34]
showed that the miRNA profiles in BM cells discriminated MDS with chromosomal
alterations from patients with normal karyotypes. Sokol et al. [35] examined
miRNA signature in BMMNCs and found deregulation of several miRNAs (increase
of miR-222 and miR-10a; decrease of miR-146a, miR-150, and let-7e) in MDS. In
our study, we analyzed miRNA expression on a genome-wide level in CD34+ BM
cells. We observed significant differences in miRNA expression between early and
advanced MDS; an apparent changeover was found between MDS with excess blast
1 (MDS-EB1) and MDS-EB2 subtypes. In particular, we identified strong
upregulation of proapoptotic miR-34a in early subtypes of MDS [36].
Although many studies were conducted regarding miRNA profiling in MDS,
there have been very few overlaps among them. This inconsistency may mirror the
heterogeneity of the disease but also may possibly be explained by variations
between the protocols and platforms used for miRNA detection.
There are several lines of evidence that many miRNAs are deregulated in MDS;
however, the functions of miRNAs in MDS pathogenesis remain rather unknown.
Identification of target genes of miRNAs in MDS and their functional proofs in both
in vitro cell cultures and in vivo animal models are necessary to realizing this goal.
3.4.1 miRNAs in MDS with del(5q)
One of the best-characterized MDS subtypes is MDS with isolated del(5q),
formerly referred to as 5q− syndrome. Haploinsufficiency of specific genes within
common deleted region (CDR) localized in 5q31.3-5q33 locus is essential for the
specific phenotype of MDS with del(5q). In addition to protein-coding genes, 13
genes encoding miRNAs are located in CDR. Most importantly, Starczynowski et al.
[37] correlated del(5q) haploinsufficiency with loss of two miRNAs that are abun-
dant in hematopoietic stem/progenitor cells (HSPCs), miR-145 and miR-146a.
Knockdown of miR-145 and miR-146a together in mouse HSPCs resulted in
thrombocytosis, mild neutropenia, and megakaryocytic dysplasia [37].
Kumar et al. [38] showed that miR-145 loss in MDS with del(5q) affects mega-
karyocyte and erythroid differentiation. These authors found that miR-145 func-
tions through the repression of FLI1 (Friend Leukemia Integration 1 Transcription
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Factor), a megakaryocyte and erythroid regulatory transcription factor. Inhibition
of miR-145 increases the production of megakaryocytic cells relative to that of
erythroid cells. Moreover, the authors proved that combined loss of miR-145 and
RPS14 (a ribosomal gene that is required for the maturation of 40S ribosomal sub-
units and that maps to the CDR) cooperates to alter erythroid-megakaryocytic
differentiation in a manner similar to that of the 5q− syndrome [38].
In our studies, we detected high expression of miR-34a in MDS del(5q) patients
[36, 39]. The expression of miR-34a is induced by p53, activating apoptosis through
inhibition of BCL2 gene (B-Cell CLL/Lymphoma 2, Apoptosis Regulator). This
result is consistent with the increased apoptosis of progenitor cells seen in MDS
del(5q).
3.4.2 miRNAs related to prognosis of MDS
Several publications have focused on miRNA expression in MDS with regard to
prognostic potential. The earliest study in this area associated miRNA profiles with
the International Prognostic Scoring System (IPSS) score [35]. A unique signature
consisting of 10 miRNAs was closely associated with IPSS risk category permitting
discrimination between lower- and higher-risk disease. Selective overexpression of
miR-181 family members was detected in higher risk MDS, indicating pathogenetic
overlap with AML. Survival analysis revealed shorter survival in patients with high
expression of miR-181 family than in patients with low miR-181 expression [35].
Another miRNA that has been identified as having prognostic value in MDS is
miR-22 [40]. This miRNA was upregulated in MDS and its level correlated with
poor survival. Transgenic mice expressing miR-22 in the hematopoietic cells
displayed reduced levels of global 5-hydroxymethylcytosine and increased HSC
self-renewal accompanied by defective differentiation. Over time, these mice
developed MDS. Interestingly, TET2 gene (Ten-Eleven Translocation 2, Tet
Methylcytosine Dioxygenase 2) was identified as a key target of miR-22 in this
context [40]. TET2 is a major regulator of DNA demethylation by conversion of
methylated cytosine into 5-hydroxymethylcytosine.
3.4.3 miRNAs in the treatment of MDS
Expression profiles of miRNAs also appear to be applicable predictors of treat-
ment responses. Lenalidomide is an immunomodulatory and antiangiogenic agent
used for the treatment of MDS with del(5q). In recent years, several studies have
analyzed miRNA expression levels before and after lenalidomide treatment in these
patients [41–44]. Oliva et al. [41] investigated expression of selected genes/miRNAs
at baseline and after 3 and 6 months of lenalidomide treatment. These authors
showed that the expression levels of miR-145, miR-146, and miR-155 gradually
increased during the course of the treatment. The significant role of miR-143 and
miR-145 in response to lenalidomide was confirmed by Venner et al. [42], who
showed that lenalidomide selectively abrogated progenitor activity in cells depleted
of miR-143 and miR-145, supporting their key role in the sensitivity to lenalidomide
in MDS with del(5q). In our studies, the most significant changes in expression
levels (decreases) after lenalidomide treatment showed miR-34a and several
miRNAs clustered within the 14q32 locus [43, 44]. However, a question remains
as to whether the changes in expression levels were due to direct response to
lenalidomide or whether they were caused by a reduction of the pathological clone.
Therapy with hypomethylating agents (HMAs) such as azacitidine and
decitabine is currently considered to be the standard therapy for higher-risk MDS
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and AML with myelodysplasia-related changes. Several studies investigated miRNA
expression with respect to HMA treatment in AML [45–47]. Blum et al. [45] pro-
posed miR-29b as a predictive factor for the stratification of older AML patients
treated with decitabine; however, this was not confirmed by other studies [46].
Butrym et al. [47] showed that low expression of miR-181 at diagnosis was a
predictor of complete remission and prolonged survival in a subset of older AML
patients treated with azacitidine.
In relation to HMA therapy in MDS, it was found that the level of extracellular
miR-21 was associated with overall response rate and progression-free survival [48].
Furthermore, reduced expression of miR-124 (caused by abnormal methylation)
was found in MDS/AML patients responding to decitabine. These patients exhibited
significantly lower expression levels of the CDK6 gene (cyclin-dependent kinase 6)
that is the target of miR-124 [49]. Moreover, hypermethylation of miR-124-3p gene
appeared to be a good prognostic marker of overall survival [50]. In our report, we
found that the overall response rate to azacitidine treatment was significantly
higher in MDS/AML patients with upregulated miR-17-3p and downregulated
miR-100-5p and miR-133b and that the high level of miR-100-5p was associated
with shorter overall survival [51].
3.4.4 Extracellular miRNAs in MDS
To date, only a few studies have investigated circulating miRNAs in MDS [48,
52–54]. Two papers [48, 52] focused on specific circulating miRNAs (miR-21, let-7a,
and miR-16) that were preselected based on information regarding their deregula-
tion in blood cells and their importance in similar diseases. Researchers monitored
the plasma/serum levels of these miRNAs and showed that their levels could serve
as prognostic markers for MDS. Kim et al. [48] showed that serum level of miR-21
was significantly associated with overall response rate and progression-free survival
in MDS patients treated with HMAs. The publication that studied let-7a and miR-16
demonstrated that high plasma levels of these miRNAs can serve as semi-invasive
markers of poor outcome for MDS patients [52].
Zuo et al. [53] measured expression of 800 human miRNAs in MDS plasma.
These authors identified a 7-miRNA signature (let-7a, miR-144, miR-16, miR-25,
miR-451, miR-651, and miR-655) as an independent predictor of survival in MDS
patients with normal karyotypes.
In our study, we investigated the spectrum (2006 human miRNAs) of circulat-
ing miRNAs in the plasma of MDS patients [54]. With regard to prognosis, the
levels of miR-27a-3p, miR-150-5p, miR-199a-5p, miR-223-3p, and miR-451a were
lower in higher risk MDS. Moreover, miR-451a was an independent predictor of
progression-free survival, and there was a significant association of miR-223-3p
with overall survival [54].
These pioneer studies suggested that plasma levels of specific miRNAs were
associated with MDS patient outcome and may add information beyond the cur-
rently used scoring systems. Despite these early promising results, there remain
insufficient data regarding the full spectrum of extracellular RNAs in MDS. To
date, the possible presence of various forms of small noncoding RNAs (apart
from mature miRNAs), pathways for their protection, and identification of their
cells of origin have not been explored in MDS. These missing information would
expand the knowledge regarding extracellular RNAs in this disease, and beyond
that, it would definitely contribute to better interpretation of alterations of individ-
ual miRNAs with the potential to become specific prognostic markers in MDS.
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4. Long noncoding RNAs
lncRNAs form perhaps the most numerous group of ncRNAs. These RNAs are
defined as protein-noncoding transcripts longer than 200 nucleotides. This length
was proposed to distinguish lncRNAs from small noncoding RNAs. In contrast with
protein-coding RNAs, lncRNAs contain only short open reading frames or
completely lack them. This group of ncRNAs is characterized by high levels of
structural and functional diversity, low levels of GC nucleotides, and lower expres-
sion levels, in contrast with protein-coding transcripts. lncRNAs are transcribed by
RNA polymerase II or III and subsequently can be spliced and polyadenylated at the
3′ end or may contain a 5′ cap, depending on their biogenesis. Their expression is
developmental and tissue-specific.
Some lncRNAs regulate (negatively or positively) the expression of genes in
trans or cis by affecting RNA polymerase II recruitment or by inducing chromatin
remodeling. In addition, antisense transcripts can pair with their specific sense
RNA, facilitating alternative splicing. When lncRNAs interact with proteins, they
can influence protein activity or localization or even help to form cellular substruc-
tures or ribonucleoprotein complexes. lncRNAs can be processed to yield small,
single- or double-stranded RNAs that can act as endogenous small interfering RNAs
(siRNAs) or miRNAs. Moreover, they can also act as “miRNA sponges” that affect
the competitive endogenous RNA (ceRNA) network. However, additional func-
tions and detailed signaling pathways of lncRNAs remain to be clarified [55].
According to their position relative to protein-coding mRNAs, lncRNAs are
further subcategorized into several groups. Long intergenic noncoding RNAs
(lincRNAs) are lncRNAs that are located between annotated protein-coding genes
and that are at least 1 kb away from the nearest protein-coding genes. Intronic
lncRNAs are coded within introns of protein-coding genes. Sense and antisense
lncRNAs are transcribed from the sense or antisense strands of protein-coding
genes and often contain exons of this gene with mutual overlap. Bidirectional
lncRNAs are oriented head-to-head with protein-coding genes within 1 kb. Bidirec-
tional lncRNA transcripts often exhibit similar expression patterns to those of their
protein-coding counterpart, suggesting that they may be subject to shared regula-
tory pressures. Another group of lncRNA is TERRA (Telomeric Repeat-Containing
RNA), transcribed from constitutive heterochromatin-rich regions, or T-UCR
(Transcribed Ultraconserved Regions), transcribed from highly conserved regions
of the genome.
Although more than 100,000 lncRNAs have been identified to date, only a small
number of them have been characterized in detail. To integrate the data describing
various lncRNAs, their expression profiles, molecular features, and functions in a
variety of cell systems, several databases containing a comprehensive list of
lncRNAs have been developed and are continually being updated. Among the most
comprehensive databases are LNCipedia (compendium of human lncRNAs,
lncipedia.org) [56], lncRNAdb (reference database for functional lncRNAs,
lncRNAdb.org) [57], and NRED (database of lncRNA expression, nred.matticklab.
com) [58].
4.1 lncRNAs in normal hematopoiesis
Recently, lncRNAs have emerged as important regulators of cell fate. These
RNAs play a variety of roles in controlling various steps in hematopoietic differen-
tiation, including maintenance of HSCs and differentiation of myeloid, erythroid,
and lymphoid lineages. To date, there have been several descriptions of lncRNAs
10
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crucial for correct function of the hematopoietic system (Table 2). The first
hematopoiesis-associated lncRNA, EGOT (Eosinophil Granule Ontogeny Tran-
script), was described in 2007. EGOT, a conserved transcript localized antisense to
ITPR1 (Inositol 1,4,5-Trisphosphate Receptor Type 1) that modulates the develop-
ment of eosinophils, is normally expressed in human CD34+ HSCs, and its expres-
sion level increases during eosinophil development, helping to regulate production
of eosinophil granule proteins [59].
The relatively well-known lncRNA, H19, maintains quiescence of adult HSCs.
The H19 transcript was in fact the first lncRNA to be identified, enriched in the
embryonic fetal liver but downregulated after birth [60]. H19 is active in long-term
HSCs and becomes gradually downregulated in short-term HSCs and multipotent
progenitors. Deletion of H19 from the maternal allele resulted in increased HSC
activation and proliferation as well as impaired repopulating ability. This effect is
mediated by derepression of maternal IGF2 (Insulin-Like Growth Factor 2) expres-
sion and by increased IGF1R (IGF1 Receptor) translation, resulting in increased
signaling through the IGF1R [61].
Zhang et al. [62] identified HOTAIRM1 (Homeobox Antisense Intergenic RNA
Myeloid 1), which is encoded within the human HOXA (Homeobox A) gene cluster
and plays a role in the differentiation of myeloid cells. The expression of this
transcript is upregulated during granulocyte differentiation. Knockdown of
HOTAIRM1 reduced transcription of HOXA1 and HOXA4 in an acute
promyelocytic leukemia cell line, resulting in a decreased expression of genes asso-
ciated with granulocyte activation, defense response, and maturation [62].
LncRNA Localization Function Reference
EGOT
(Eosinophil Granule Ontogeny
Transcript)
3p26.1, antisense to
ITPR1 gene
Modulates development of
eosinophils
[59]
H19 11p15.5, antisense to
IGF2
Maintains quiescence of adult
HSCs
[60]
HOTAIRM
(Hox Antisense Intergenic RNA
Myeloid 1)
7p15.2, encoded within
the HOXA gene cluster
Induces differentiation of
myeloid cells
[62]
lincRNA-EPS Mouse 4qC7 Promotes red blood cell
maturation
[63]
T-ALL-R-LncR1 6q24.3 Induces apoptosis in T-ALL [66]
LUNAR1
(Leukemia-Induced Noncoding
Activator RNA)
15q26.3 Positive regulator of cell
division
[67]
HOTAIR
(Hox Transcript Antisense
RNA)
12q13.13, encoded
within the HOXC gene
cluster
Oncogene, promotes
chromatin relocalization
[68]
MALAT-1
(Metastasis Associated Lung
Adenocarcinoma Transcript)
11q13.1 Regulates transcription and
cell cycle
[69]
MEG3
(Maternally Expressed Gene 3)
14q32.2 Tumor suppressor [70]
XIST
(X-Inactive Specific Transcript)
Xq13.2 Regulates X chromosome
inactivation during
embryogenesis
[73]
Table 2.
Examples of lncRNAs involved in normal and malignant hematopoiesis.
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Hu et al. [63] studied the lncRNA transcriptome of the erythroid lineage and
uncovered numerous erythroid-specific lncRNAs that become induced during ter-
minal differentiation of mouse fetal liver red blood cells in vivo. These authors
showed that lincRNA-EPS (erythroid prosurvival) acts to promote red blood cell
maturation by downregulating proapoptotic pathways. Knockdown of lincRNA-
EPS severely compromised terminal differentiation of erythroid progenitors and
resulted in elevated apoptosis. Conversely, its ectopic expression protected ery-
throid progenitors from apoptosis triggered by erythropoietin starvation. Func-
tional studies indicated that lincRNA-EPS acts by repressing a number of
proapoptotic proteins, most prominently the caspase-activating adaptor protein
Pycard [63].
Recent studies have also provided evidence for the importance of several
lncRNAs in immune cell function. For example, lncRNA NeST (Nettoie Salmonella
pas Theiler’s, cleanup Salmonella not Theiler’s), also named Tmevpg1, modulates
the ability of mice to respond to viral and bacterial infections. NeST is specifically
expressed by the TH1 subset of helper T cells. The expression of NeST regulates the
degree of inflammation induced by infecting pathogens, such as Thelier’s virus or
Salmonella [64]. lncRNA-Cox2 (cyclooxygenase 2) acts during inflammatory sig-
naling by modulating the expression of several immune response genes via interac-
tions with regulatory complexes [65].
4.2 lncRNAs in malignant hematopoiesis
lncRNAs not only participate in normal hematopoiesis but also contribute to the
pathogenesis of hematologic malignancies, representing a new class of potential
biomarkers and therapeutic targets. These RNAs have significantly different
expression levels in primary tumors and metastases, functioning both as oncogenes
or as tumor suppressors. Some cancer-related lncRNAs could affect the develop-
ment and progression of tumor by means of p53, polycomb repressive complex 2
(PRC2), and other signaling pathways. Others are not observed in normal tissue but
are detected in cancer. For example, T-ALL-R-lncR1 appears to induce (together
with protease-activated receptor 4 (PAR-4)) cellular apoptosis in T cell acute lym-
phoblastic leukemia cells (T-ALL) [66]. LUNAR1 (leukemia-induced noncoding
activator RNA) is highly expressed in T-ALL cells, and its expression is dependent
on signaling through the oncogenic NOTCH1 receptor [67]. lncRNAs HOTAIR
(homeobox transcript antisense RNA) and MALAT-1 (metastasis-associated lung
adenocarcinoma transcript) are associated with metastasis and recurrence [68, 69].
4.2.1 lncRNA deregulation in MDS
The first study describing lncRNA in the context of MDS was published in 2010
by Benetatos et al. [70] who studied lncRNA MEG3 (maternally expressed gene 3).
Abnormal methylation of its promoter was observed in a third of MDS patients and
in half of AML patients [70]. MEG3 was the first lncRNA described to have a tumor
suppressor function. MEG3 is expressed in many human normal tissues, and
numerous studies have demonstrated that its expression level is lost in various
cancers. Low expression of MEG3 is associated with an increased risk of metastasis
and poor prognosis in cancer patients [71, 72].
In 2013, Yildirim et al. [73] conditionally deleted lncRNA XIST (X-inactive
specific transcript) in mice hematopoietic cells. XIST is perhaps the most well-
understood lncRNA to date. This lncRNA is located on the X chromosome and is
required for X chromosome inactivation during embryogenesis. Yildirim et al. [73]
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demonstrated that mutant females developed a highly aggressive myeloproliferative
neoplasm and MDS (mixed MPN/MDS) with 100% penetrance.
The first study examining the deregulation of lncRNAs on a genome-wide level
in MDS was published in 2017 [74]. The authors combined NGS and microarray
data in CD34+ BM cells and identified several lncRNAs (linc-ARFIP1-4, linc-
TAAR9-1, lincC2orf85, linc-RNFT2-1, and linc-RPIA) deregulated in MDS-EB2. In
the same year, Yao et al. [75] profiled lncRNA expressions in 176 adult patients with
primary MDS and identified four lncRNAs (TC07000551.hg.1, TC08000489.hg.1,
TC02004770.hg.1, and TC03000701) with expression levels significantly associated
with overall survival. Subsequently, the authors constructed a risk-scoring system
with the weighted sum of these four lncRNAs. Higher lncRNA scores were associ-
ated with higher marrow blast percentages, higher-risk subtypes of MDS, complex
cytogenetic changes, and mutations in RUNX1, ASXL1, TP53, SRSF2, and ZRSR2,
whereas they were inversely correlated with the SF3B1 mutation. Patients with
higher lncRNA scores had significantly shorter overall survival and higher 5-year
leukemic transformation rate than did those with lower scores [75].
Although increasing numbers of deregulated lncRNAs are currently being
described in MDS, only a few have been functionally characterized so far.
Transcriptomic data may be used to construct network modules consisting of
lncRNAs and protein-coding genes to enable functional analysis of lncRNAs with
unknown functions. These networks are subsequently linked with annotated sig-
naling pathways and gene ontologies. The resulting outputs provide a degree of
functional annotation for differentially expressed lncRNAs in the disease and their
potential roles in pathophysiology [74].
5. Other types of noncoding RNAs in MDS
Only very limited information regarding other groups of ncRNAs have been
published for MDS to date. However, we can anticipate that introduction of next-
generation sequencing of RNAs (so-called RNA-seq) will bring to MDS research
many novel insights regarding various ncRNAs in the near future. This technology
enables sensitive global detection of various RNAs across an unparalleled dynamic
range. Particularly, small RNA-seq is predominantly used for detection of miRNAs.
However, during library preparation, small RNAs are selected by electrophoresis
with sizes typically ranging from 20 to 50 nt. This range of size selection allows for
the capture of many other species of small RNAs in addition to miRNAs.
5.1 Piwi-interacting RNAs
In 2011, Beck et al. [76] conducted one of the early studies to apply small RNA-
seq in MDS. These authors compared expression of small RNAs between low-grade
(refractory anemia, RA) and high-grade (MDS-EB2) MDS patients and demon-
strated the first evidence of piwi (P-element-Induced Wimpy Testis)-interacting
RNAs (piRNAs) in MDS BM cells and their particular enrichment in low-grade
MDS. PiRNAs are a relatively newly defined class of small ncRNAs with lengths
from 26 to 32 nt. These RNAs lack sequence conservation and are more complex
than miRNAs. PiRNAs have been linked to both epigenetic and posttranscriptional
gene silencing of retrotransposons and other genetic elements in germline cells,
particularly those involved in spermatogenesis.
Transcription of particular piwi proteins (piwil1 and piwil2) that are required for
the accumulation of piRNAs was also significantly upregulated in RA [76]. Recent
studies indicated that the piwi-piRNA complex may have a role in
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posttranscriptional silencing of damaged DNA fragments and that interrupting
piwi-piRNA formation can lead to DNA double-strand breaks [77]. In summary, the
study from Beck et al. [76] suggested that the enrichment of piRNAs in low-grade
MDS may potentially protect DNA from the accumulation of mutations, a mecha-
nism not observed in high-grade MDS. Moreover, they proposed that piRNAs might
be used as diagnostic markers for low-grade MDS; however, further studies of
piRNA roles in MDS pathogenesis are warranted.
5.2 Transfer RNAs
The abovementioned pioneer study from Beck et al. [76] also provided an early
insight into the deregulation of tRNAs in MDS. The authors showed that ratios of
tRNA to rRNA were significantly higher in MDS-EB2 compared to those of RA and
controls. Because tRNAs are building blocks for protein synthesis and are required
during translation, this may indicate an increased regulation of translation at this
disease stage. Interestingly, a significant increase of tRNAs in tumor samples was
reported by Pavon-Eternod et al. [78] In addition, tRNAs have been shown to
inhibit cytochrome c-activated apoptosis [79]. Taken together, Beck et al. [76]
hypothesized that high tRNA content seen in EB2 may contribute to the two well-
known characteristics of high-grade MDS, decreased apoptosis, and high rate of
leukemic transformation.
Guo et al. [80] performed small RNA-seq in paired pre- and posttreatment
samples from MDS patients receiving therapy with HMAs. In the sequencing data,
the number of reads aligned to tRNA-derived small RNAs (tDRs) (78.81%) vastly
outnumbered those aligning to miRNAs (4.43% of reads). The tRNA fragments that
were captured by miRNA-seq might be a result of either active cleavage or artifacts
of the miRNA-seq library construction. The authors identified six tDR fragments
that were differentially expressed between MDS and normal samples. Three tDRs
demonstrated increased expression in MDS (chrM.tRNA10.TC, chr12.tRNA8.
AlaTGC, and chr16.tRNA4.ProAGG), while three were decreased (chr1.tRNA58-
LeuCAA, chr19.tRNA8-SeC(e)TCA (SeC(e)TCA), and chr19.tRNA4-ThrAGT).
Moreover, they identified a panel of four tRNA fragments (chr6.tRNA157.ValCAC,
chr11.tRNA17.ValTAC, chrM.tRNA12.TS1, and chrX.tRNA4.ValTAC), whose com-
bined expression in the pretreatment samples together was predictive of the likeli-
hood of response. Deeper focus on mitochondrial tRNAs revealed that MT-TS1
(mitochondrially encoded tRNA serine 1) was the only mitochondrial tRNA to have
a significant association with treatment response [80].
6. Conclusions
The discovery of ncRNAs has initiated a new era in molecular biology,
completely changing our view of “junk” DNA that it is no longer considered
unnecessary ballast. Mouse models have clearly demonstrated key functions of
ncRNAs in regulatory networks and their ability to significantly influence biological
processes. In the hematopoietic system, ncRNAs represent important regulators of
HSC “stemness” and differentiation; therefore, it is not surprising that deregulation
of ncRNAs also occurs in MDS.
Currently, we possess comprehensive information regarding the impact of
miRNA deregulation on the pathogenesis of MDS. The efforts of current research
activities aim to apply these findings to clinical practice, testing the potential diag-
nostic/prognostic value of selected miRNAs for MDS. However, miRNAs also rep-
resent promising therapeutic agents or targets. miRNA-based drugs are designed to
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reduce the expression of oncogenic miRNAs or, conversely, to increase levels of
miRNAs with tumor suppressor functions. Unlike targeted inhibition or activation
of a single protein-coding gene, the administration of miRNA antagonists or their
mimics may potentially improve the desired effects, as these molecules can regulate
several genes, often in specific signaling pathways implicated in tumorigenesis.
Several pharmaceutical companies already have miRNA therapeutics in their devel-
opmental pipelines [81]. In 2012, the first cancer-targeted miRNA drug, MRX34 (a
liposome-based miR-34 mimic), entered phase I clinical trials in patients with
advanced hepatocellular carcinoma, and this mimic has attracted considerable
attention from both academic researchers and pharmaceutical companies [82].
MRG-106, a synthetic antagonist of miRNA-155, is currently being tested by
MIRagen Therapeutics in patients with cutaneous T-cell lymphoma [83]. However,
testing miRNAs as potential therapeutic agents or targets in MDS therapy still
requires initial exploration in in vitro models before evolving to future clinical trials.
Information regarding the contribution of other categories of ncRNAs, including
lncRNAs, to the pathogenesis of MDS remains scarce. However, given the large
number of ncRNAs encoded in the human genome and the complexity of their
interactions, it can be expected that, in the near future, we will reveal a number of
ncRNAs involved in MDS. It can also be anticipated that we will identify new
predictive markers of progression and responses to therapy among these molecules.
To conclude, the diagnostic and therapeutic possibilities of ncRNAs undoubtedly
have profound potential in MDS. However, although the effects of some miRNAs
have already been demonstrated, it is certain that the importance of ncRNAs in
MDS will be fully understood only in the future and that many years of research and
clinical trials remain before the eventual application of ncRNAs in clinical practice
to classify, monitor, and treat this disease.
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